Accelerated partial breast irradiation: Bifractionated 40 Gy in one week. A French pilot phase II study

作者：Bourgier C^*; Pichenot C; Verstraet R; Heymann S; Biron B; Balleyguier C; Delaloge S; Mathieu M C; Uzan C; Garbay J R; Bourhis J; Taghian A; Marsiglia H

来源：Cancer Radiotherapie, 2010, 14(8): 718-726.

DOI：10.1016/j.canrad.2010.05.006

• Accelerated partial breast irradiation
• 3D conformal
• Hypofractionation

Purpose. - Since 2009, accelerated partial breast irradiation (APBI) in North America has been allowed to be used for selected group of patients outside a clinical trial according to the ASTRO consensus statement. In France, accelerated partial breast irradiation is still considered investigational, several clinical trials have been conducted using either intraoperative (Montpellier) or Mammosite (R) (Lille) or brachytherapy modality (PAC GERICO/FNCLCC). Here, we report the original dosimetric results of this technique.
Patients and methods. - Since October 2007, Institut Gustave-Roussy has initiated a phase II trial using 3D-conformal accelerated partial breast irradiation (40 Gy in 10 fractions BID in 1 week). Twenty-five patients with pT1N0 breast cancer were enrolled and were treated by two minitangent photons beams (6 MV) and an "en face" electron beam (6-22 MeV).
Results. - The mean clinical target volume and planning target volume were respectively 15.1 cm(3) (range: 5.2-28.7 cm(3)) and 117 cm(3) (range: 52-185 cm(3)). The planning target volume coverage was adequate with at least a mean of 99% of the volume encompassed by the isodose 40 Gy. The mean dose to the planning target volume was 41.8 Gy (range: 41-42.4 Gy). Dose inhomogeneity did not exceed 5%. Mean doses to the ipsilateral lung and heart were 1.6 Gy (range: 1.0-2.3 Gy) and 1.2 Gy (range: 1.0-1.6 Gy), respectively.
Conclusion. - The 3D conformal accelerated partial breast irradiation using two minitangent and "en face" electron beams using a total dose of 40 Gy in 10 fractions BID over 5 days achieves appropriate planning target volume coverage and offers significant normal-tissue sparing (heart, lung). Longer follow-up is needed to evaluate the tissue tolerance to this radiation dose.

• 出版日期2010-12